Skip to main content

Effectiveness of Various Processing Steps for Viral Clearance of Therapeutic Proteins: Database Analyses of Commonly Used Steps

  • Protocol
  • First Online:
Therapeutic Proteins

Part of the book series: Methods in Molecular Biology ((MIMB,volume 899))

Abstract

The successful implementation of any biologically derived product in human clinical trials and as a marketed biopharmaceutical requires the critical utilization of effective viral clearance steps. As biologic products have inherent risks of potentially carrying and or amplifying adventitious viruses that may be present in or introduced into the original materials, a number of processing steps are needed to provide adequate virus removal. Some common process steps are introduced into downstream purification schemes that provide a physical means to separate and/or remove viruses from the therapeutic protein. The physical steps often include virus-removing filters and chromatographic resins in column or membrane configurations, but can also include the introduction of irradiation, high heat steps, or other means for destroying the infectivity of a virus. Chemical treatment steps are often utilized as a means to inactivate a wide variety of virus types.

A general overview is provided that describes the most commonly used techniques for virus removal or inactivation for the validation of virus clearance. Data sets from studies performed at WuXi AppTec for a wide variety of biologics reveal a number of steps that provide guidance for the design of process steps dedicated to viral clearance. The overall efficiency of several process steps reveals a number of efficient, robust steps, such as nanofiltration which can be designed for removal of almost all viral species. Exposure to a low pH or solvent detergent is also a robust step for inactivating enveloped virus. Steps with greater variances in predictability include chromatography steps such as capture columns and anion exchange resins. A lower removal capacity is typically expected for other chromatography steps such as cation exchange steps.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) (1997). “Points to consider in the manufacture and testing of monoclonal antibody products for human use.” 94D-0259

    Google Scholar 

  2. US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) (1993) “Points to consider in the characterization of cell lines used to produce biologicals”

    Google Scholar 

  3. Committee for Proprietary Medicinal Products (CPMP) (1997) “International conference on harmonization (ICH) Topic Q 5 A. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.” Consensus Guideline ICH Viral Safety Document: Step 4. CPMP/ICH/295/95

    Google Scholar 

  4. Committee for Proprietary Medicinal Products (CPMP) (1996) “The design, contribution and interpretation of studies validating the inactivation and removal of viruses.” CPMP/BWP/268/95

    Google Scholar 

  5. European Medicines Agency (EMEA) (2009) “Guideline on virus safety evaluation of biotechnological investigational medicinal products.” EMEA/CHMP/BWP/398498

    Google Scholar 

  6. American National Standard (2007). “Medical devices utilizing animal tissues and their ­derivatives—Part 3: validation of the elimination and/or inactivation of viruses.” ANSI/AAMI/ISO 22442-3

    Google Scholar 

  7. Garnick RL (1996) Experience with viral contamination in cell culture. Dev Biol Stand 88:49–56

    PubMed  CAS  Google Scholar 

  8. Skrine J (2010) A biotech production facility contamination case study—Minute virus of mice. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec

    Google Scholar 

  9. Moody M (2010) MVM contamination—A case study: detection, root cause determination and corrective actions, at merrimack pharmaceuticals. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec

    Google Scholar 

  10. Jones N (2010) Identification and remediation of a cell culture virus contamination, at genzyme. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec

    Google Scholar 

  11. Pierard I (2010) Contamination by porcine circo virus: findings, investigations and learning, at GSK. Presented at PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec

    Google Scholar 

  12. Norling L (2011) Virus inactivation and application of the modular approach. Presented at IBC’s 8th international conference viral safety for biologicals. Orlando, FL, 24–25 Feb

    Google Scholar 

  13. Floyd R, Sharp DG (1978) Viral aggregation: effects of salts on the aggregation of poliovirus and reovirus at low pH. Appl Environ Microbiol 35:1084–1094

    PubMed  CAS  Google Scholar 

  14. Zhou J (2008) Methods for removing viral contaminants during protein purification. United States Patent Application Publication. Pub. No.: US 2008/0132688 A1. Pub. Date: 5 Jun

    Google Scholar 

  15. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Yuan Xu (2003) Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82: 321–329

    Article  PubMed  CAS  Google Scholar 

  16. Brough H, Antoniou C, Carter J, Jakubik J, Xu Y, Lutz H (2002) Performance of a novel Viresolve NFR virus filter. Biotechnol Prog 18: 782–795

    Article  PubMed  CAS  Google Scholar 

  17. Gottschalk U (2009) Process scale purification of antibodies (Chapters 4, 7, 8, 9). Wiley, Hoboken, NJ

    Google Scholar 

  18. Lute S et al (2008) Robustness of virus removal by Protein A chromatography is independent of media lifetime. J Chromatogr A 1205:17–25

    Article  PubMed  CAS  Google Scholar 

  19. Technical Report No. 47 (2010) Preparation of virus spikes used for viral clearance studies. Parenteral Drug Association (PDA) Bethesda, MD

    Google Scholar 

  20. Technical Report No. 41 (2008) Virus filtration. Parenteral Drug Association (PDA) Bethesda, MD

    Google Scholar 

  21. Cherney B (2010) Application of quality of design in the control of adventitious viruses: gaps in the current processes in the prevention of virus contaminants. PDA/FDA adventitious viruses in biologics: detection and mitigation strategies workshop. Bethesda, MD, 1–3 Dec

    Google Scholar 

  22. Norling L et al (2005) Impact of multiple re-use of anion exchange chromatography media on virus removal. J Chromatogr A 1069:79–89

    Article  PubMed  CAS  Google Scholar 

  23. Strauss D et al (2010) Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody production. Biotechnol Prog 26: 750–755

    Article  PubMed  CAS  Google Scholar 

  24. Strauss D et al (2009) Understanding the mechanism of virus removal by Q Sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng 104:371–380

    Article  PubMed  CAS  Google Scholar 

  25. Miesegaes G, Lute S, Brorson K (2010) Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng 106:238–246

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph V. Hughes .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Cipriano, D., Burnham, M., Hughes, J.V. (2012). Effectiveness of Various Processing Steps for Viral Clearance of Therapeutic Proteins: Database Analyses of Commonly Used Steps. In: Voynov, V., Caravella, J. (eds) Therapeutic Proteins. Methods in Molecular Biology, vol 899. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-921-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-921-1_18

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-920-4

  • Online ISBN: 978-1-61779-921-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics